MedTrace Logo

Osteoarthritis of the Knee Pain Study Using a CBD and THC Sublingual Tablet

NCT04195269 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-04-14

No results posted yet for this study

Summary

This study is a prospective Phase 2, drug controlled, open-label study to evaluate the safety and efficacy of Pure Green sublingual tablets for the treatment of pain associated with osteoarthritis of the knee.

Conditions

  • Osteoarthritis, Knee
  • Pain

Interventions

DRUG

Test Article

10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.

Sponsors & Collaborators

  • Pure Green

    lead INDUSTRY

Principal Investigators

  • Debra Kimless, M.D. · Chief Medical Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-20
Primary Completion
2020-06-30
Completion
2020-07-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04195269 on ClinicalTrials.gov